Clinical trials: Functional Disorder of Gastrointestinal Tract
- Condition Functional Disorder of Gastrointestinal Tract
- Funder type Industry (pharma, biotech, devices)
Functional Gastrointestinal Disorders
Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus
In this study researchers want to learn more about the effectiveness of Iberogast® in patients with irritable stomach and concomitant chronic or recurrent heartburn and backward flow of stomach liquid into the esophagus.
- Trial name
- NCT04059900
- Testing
- STW5 (Iberogast®, BAY98-7411)
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Bayer
Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases), Irritable Bowel Syndrome With Constipation (IBS-C)
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
The objective of this study is to evaluate the long-term safety and efficacy of linaclotide in post-marketing use.
- Trial name
- NCT03471728
- Testing
- linaclotide
- Where
- 47 sites in Japan
- Volunteers
- 2,475 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Effect of BIO-K+ on Symptoms of Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and effectiveness of Bio-K+ on symptoms of IBS.
- Trial name
- NCT01545037
- Testing
- L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®
- Where
- 3 sites in United States
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Bio-K Plus International Inc.
Irritable Bowel Syndrome
Effect of Probiotic Supplement on Bowel Function
The purpose of this study is to analyse the effect of probiotic supplement on symptoms of irritable bowel syndrome.
- Trial name
- IBS2 (NCT01475929)
- Testing
- Probiotic supplement
- Where
- Finland
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Danisco
Irritable Bowel Syndrome
Asimadoline for the Treatment of Subjects With Irritable Bowel Syndrome
The purpose of this study is to evaluate the safety and efficacy of different doses of asimadoline in the treatment of patients with irritable bowel syndrome.
- Trial name
- NCT00454688
- Testing
- Asimadoline
- Where
- 112 sites in United States
- Volunteers
- 596 people
- Sponsor
- Tioga Pharmaceuticals
Irritable Bowel Syndrome
Efficacy and Safety of Alflorex Bei Reizdarm in Patients With Irritable Bowel Syndrome
This Post-Market Clinical-Follow Up (PMCF) study gains data on the efficacy and safety of "Alflorex bei Reizdarm", a probiotic based on Bifidobacterium longum 35624, in the daily use by irritable bowel syndrome (IBS) patients.
- Trial name
- NCT04859075
- Testing
- Bifidobacterium longum 35624
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Medice Arzneimittel Pütter GmbH & Co KG
Irritable Bowel Syndrome
Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)
The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies: Strategy A = MeteoSpasmyl®, on-demand therapy Strategy B = standard of care chosen by the physician
- Trial name
- NCT01404923
- Testing
- anti spasmodic agents, alverine citrate, simeticone
- Volunteers
- 436 people
- Sponsor
- Laboratoires Mayoly Spindler
Cystic Fibrosis
A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF…
- Trial name
- NCT03447249
- Testing
- VX-659/TEZ/IVA, IVA
- Where
- 101 sites in United States, Australia and 9 more
- Volunteers
- 385 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Irritable Bowel Syndrome
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of different oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189813
- Testing
- YM060
- Where
- 45 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 691 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo
The study shall prove whether treatment of irritable bowel syndrome with Iberogast is superior to placebo regarding the main criterium "pain"
- Trial name
- NCT01940848
- Testing
- STW5 (Iberogast, BAY98-7411)
- Where
- 19 sites in Germany
- Volunteers
- 243 people
- Sponsor
- Bayer
Irritable Bowel Syndrome, Diarrhea
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
The purpose of this study is to evaluate how well brenipatide (LY3537031) is tolerated, what side effects may occur, and the safety and efficacy in participants with Irritable Bowel Syndrome-Diarrhea (IBS-D).
- Trial name
- RENEW-IBS-D (NCT07545759)
- Testing
- LY3537031
- Where
- 89 sites in United States, Belgium and 8 more
- Volunteers
- 531 people
- Sponsor
- Eli Lilly and Company
Irritable Bowel Syndrome
Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)
Study is to assess the effectiveness of TC-6499 in the treatment of constipation predominant IBS patients over a 28-day period.
- Trial name
- NCT01149200
- Testing
- TC-6499
- Where
- 2 sites in United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Breast Feeding, Constipation
A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically
The purpose of this study is to determine the amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk after multiple, once daily doses of linaclotide (72 μg, 145 μg, or 290 μg) in lactating women…
- Conditions
- Breast Feeding, Constipation, Irritable Bowel Syndrome
- Trial name
- LIN-PK-01 (NCT02220348)
- Testing
- linaclotide
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Forest Laboratories
Small Intestinal Bacterial Overgrowth, SIBO
The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms
The goal of this study is to test the effect of a probiotic formulation on gastrointestinal symptoms, gut and small intestine microbiota in participants suffering from small intestinal bacterial overgrowth (SIBO).
- Trial name
- NCT06317441
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Nimble Science Ltd.
Gastrointestinal Disorder, Functional, Regurgitation, Gastric
Transition to Infant Formula Feeding on Gastrointestinal Regurgitation (TIGER) Study
To compare the frequency of regurgitation and other digestive outcomes between infants who receive an infant formula based on whole goat milk and an infant formula based on cow milk proteins during the transition period from…
- Conditions
- Gastrointestinal Disorder, Functional, Regurgitation, Gastric, Colic, Infantile, Constipation - Functional
- Trial name
- TIGER (NCT05363553)
- Testing
- Infant formula based on whole goat milk, infant formula based on cow milk proteins
- Where
- Thailand
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Dairy Goat Co-operative (N.Z.) Limited
Irritable Bowel Syndrome
Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome
Subjects with confirmed diagnosis of Irritable Bowel Syndrome will be blinded and randomly assigned to one of two groups, the low FODMAP diet or the conventional IBS diet group.
- Trial name
- NCT02450370
- Testing
- Low FODMAP diet, Conventional IBS diet group
- Where
- Hong Kong
- Volunteers
- 103 people
- Sponsor
- Hong Kong Sanatorium & Hospital
Irritable Bowel Syndrome (IBS)
Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients
This is an open labeled, one-armed real-world study in IBS-patients. All participants will receive active treatment for 12 weeks.
- Trial name
- GRIPS (NCT03550742)
- Testing
- Fuco-N-Tetraose
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Glycom, Inc.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Irritable Bowel Syndrome
Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity
The main objective of this observatory is to evaluate the effect of Bifidobacterium longum 35624 on the quality of life of IBS patients having different subtypes of transit pattern and different level of symptom severity
- Trial name
- NCT04662502
- Testing
- Bifidobacterium longum 35624
- Where
- France
- Volunteers
- 220 people
- Sponsor
- Biocodex
Irritable Bowel Syndrome
Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea
The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea…
- Trial name
- NCT01130272
- Testing
- Eluxadoline
- Where
- 288 sites in United States
- Volunteers
- 807 people
- Sponsor
- Furiex Pharmaceuticals, Inc